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Abstract
Background: Cancer shows a great diversity in its clinical behavior which cannot be easily predicted using the
currently available clinical or pathological markers. The identification of pathways associated with lymph node
metastasis (N+) and recurrent head and neck squamous cell carcinoma (HNSCC) may increase our understanding
of the complex biology of this disease.
Methods: Tumor samples were obtained from untreated HNSCC patients undergoing surgery. Patients were
classified according to pathologic lymph node status (positive or negative) or tumor recurrence (recurrent or
non-recurrent tumor) after treatment (surgery with neck dissection followed by radiotherapy). Using microarray
gene expression, we screened tumor samples according to modules comprised by genes in the same pathway or
functional category.
Results: The most frequent alterations were the repression of modules in negative lymph node (N0) and in non-
recurrent tumors rather than induction of modules in N+ or in recurrent tumors. N0 tumors showed repression of
modules that contain cell survival genes and in non-recurrent tumors cell-cell signaling and extracellular region
modules were repressed.
Conclusions: The repression of modules that contain cell survival genes in N0 tumors reinforces the important role
that apoptosis plays in the regulation of metastasis. In addition, because tumor samples used here were not
microdissected, tumor gene expression data are represented together with the stroma, which may reveal signaling
between the microenvironment and tumor cells. For instance, in non-recurrent tumors, extracellular region module
was repressed, indicating that the stroma and tumor cells may have fewer interactions, which disable metastasis
development. Finally, the genes highlighted in our analysis can be implicated in more than one pathway or
characteristic, suggesting that therapeutic approaches to prevent tumor progression should target more than one
gene or pathway, specially apoptosis and interactions between tumor cells and the stroma.
Background
Head and neck squamous cell carcinomas (HNSCC) are
the seventh most common solid malignancy in the United
States, accounting for more than 47,000 new cancer cases
per year [1]. Surgery of patients clinically diagnosed with
lymph node metastasis (N+) usually involves neck
dissection, which can cause disfigurement, functional
impairment, and pain. However, after histological exami-
nation, more than 30% of clinically N+ patients turn out
to be pathologically metastasis-free (pN0) [2].
Clinically N0 patients may have occult node metastasis
in up to 50% of the cases; in other words, these patients
are pathologically N+ (pN+) [3]. Within two years of
follow-up, these patients may develop metastatic disease
[4]. On the other hand, around 50% of N0 patients do
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patients undergo neck dissection unnecessarily. Due to
limitations in detecting lymph node metastasis before
surgery, both pN+ and pN0 patients may receive inap-
propriate treatment. This indicates that a better under-
standing of the biology of HNSCC is urgently needed.
HNSCC also shows a great diversity in its clinical
behavior after treatment, which cannot be predicted
using the currently available clinical or pathological
markers. Despite tumor complexity, many studies have
unsuccessfully tested the prognostic value of single
g e n e sa sm a r k e r sf o rH N S C C .T h em o s ts t u d i e dg e n e s
related to the onset of HNSCC are epidermal growth
factor receptor (EGFR), Cyclin D1, p53,a n dH u m a n
Papilloma Virus (HPV), while the expression of matrix
metallopeptidases (MMP) and vascular endothelial
growth factor (VEGF) are associated with the metastatic
phenotype (for review see references [5,6]). Despite the
development of target therapies against EGFR and
VEGFR, metastasis affects 40 to 50% of advanced
HNSCC patients [7-9].
Microarray studies provide simultaneously measure-
ment of thousands of genes, having therefore been used
to identify many differentially expressed genes and
expression profiles in HNSCC. For instance, a molecular
signature of 102 genes was identified and independently
validated for detection of lymph node metastasis with
overall accuracy of 86% [10]. Later, numerous combina-
tions of genes were used for predicting lymph node
status, suggesting that molecular signatures based on a
large number of genes are less likely to be biased
towards specific samples [11]. Unfortunately, the use of
expression profiles has not been incorporated into the
clinic due to a lack of standards in experimental design
and heterogeneous results [12].
According to the functional analysis of microarray
data described by Segal et al. [13], a group of tumor
samples can be characterized according to the behavior
of modules. These modules include clusters of genes
that belong to the same pathway or functional category
[14], [15].
Cancer is a multifaceted phenomenon that involves
activation and/or disruption of various cellular pro-
cesses. Thus, the identification of pathways or groups of
genes such as those involved in the development of
lymph node metastasis and recurrent disease may help
us understand the complex biology of HNSCC.
Previously, our group successfully applied the func-
tional analysis strategy to identify altered modules in
pre-malignant and adenocarcinomas of the stomach and
esophagus [16]. Here we describe the application of this
analysis to screen modules of genes with altered expres-
sion in poor prognosis HNSCC (positive lymph node or
recurrent tumors). Our findings suggest that progression
of HNSCC may be inhibited by loss of expression of
genes related to cell survival and interactions with the
stroma.
Methods
Patients and tissue samples
The study was approved by our institutional review
board and all patients signed a pre-informed consent.
Samples were obtained from surgery of patients with
untreated HNSCC at the Head and Neck Surgery and
Otorhinolaryngology Department of the Hospital AC
Camargo (São Paulo, Brazil) (Table 1). During surgery,
Table 1 Clinical information of patients with head and neck squamous cell carcinoma
pN+ pN0 Recurrent* Non-recurrent*
Samples 61 20 20 27
Oral cavity (%, n) 55.7 (34) 65.0 (13) 50.0 (10) 44.4 (12)
Oropharynx (%, n) 44.3 (27) 35.0 (7) 35.0 (7) 40.7 (11)
Hypopharynx (%, n) 0 0 5.0 (1) 7.4 (2)
Larynx (%, n) 0 0 10.0 (2) 7.4 (2)
Age (mean in years**) 56.9 (23-85) 61.2 (35-88) 57.2 (39-74) 55.5 (23-78)
Male gender (%, n) 82.0 (50) 80.0 (16) 90.0 (18) 74.1 (20)
Smoking (%, n) 83.6 (51) 70.0 (14) 95.0 (19) 74.1 (20)
Alcohol (%, n) 67.2 (41) 50.0 (10) 80.0 (16) 63.0 (17)
pT3-4 (%, n) 73.8 (45) 50.0 (10) 80.0 (16) 59.3 (16)
Follow-up (years**) 0 - 9.03 0,01 - 7,80 0.37 - 3.47 2.41 - 9.03
Locoregional recurrence or 44.3 (27) 25.0 (5)
distant metastasis (%, n)
Note: *All patients were submitted to surgery and neck dissection, presented pathologic positive lymph node status, and were treated with adjuvant
radiotherapy. Recurrence was considered as locoregional and/or distant metastasis after treatment (biopsy proven or by imaging). **minimum - maximum.
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patients received chemotherapy before or after surgery.
All patients whose samples were used in the comparison
between recurrent versus non-recurrent tumors were
treated with adjuvant radiotherapy. Tumor samples were
snap-frozen in liquid nitrogen. Before RNA extraction,
diagnosis was confirmed by hematoxylin-eosin staining.
Frozen samples were hand dissected for removal of nor-
mal cells, necrosis, and infiltrating inflammatory cells.
Microarray expression analysis
The experimental procedures and raw data are available
at the Gene Expression Omnibus, according to the
Minimum Information About a Microarray Experiment
standards [GEO:GSE22243] [17]. Total RNA was
extracted using Trizol (Invitrogen, Carlsbad, CA). RNA
quality was assessed by spectrophotometry and gel elec-
trophoresis. To be considered as high-quality, the RNA
had to have a 260/280 ratio higher than 1.7 and an 18S/
28S rRNA ratio ~2. Amplification of the mRNA was
done using a T7-based protocol [18] and cDNA was
indirectly labeled with Alexa Dye 555 or 647 (Invitrogen,
Carlsbad, CA). Samples and a common RNA reference
were hybridized overnight at 42°C in dye-swap to a
4,800-element in-house printed microarray [GEO:
GPL8173] [19], enriched with cancer-related ESTs
derived from the Human Cancer Genome Project [20],
[21]. After washing, slides were scanned on a confocal
laser scanner (ScanArray Express, Perkin-Elmer Life
Sciences, Boston, MA) and data were extracted with
ScanArray Express software.
Functional modules analysis
The analysis was carried in R [22], [23] plus Bioconduc-
tor’s maigesPack [24]. Background-subtracted spot
intensities were normalized by Loess using span 0.4 and
degree 2. Next, we searched for gene expression patterns
associated with clinical/pathological parameters but
which were not necessarily associated with individual
samples, following the method described by Segal et al.
[13]. For that, we defined functional modules according
to the following databases: Biocarta [25], GeneDecks
[26], Gene Ontology [27], and Kyoto Encyclopedia of
Genes and Genomes Pathway Database (KEGGPD) [28].
334 modules could be represented by the EST sequences
spotted on the microarray chip (Additional File 1).
According to Segal and colleagues [13], a gene in each
sample is induced when its expression is two times
higher than the average expression in all samples, and is
repressed when its expression is two times lower than
the same average. Next, we identified the modules in
each sample containing a higher than expected fraction
of induced or repressed genes. For the corresponding
hypothesis test, the fraction of induced and repressed
genes within each module in a sample would, under the
null hypothesis, show a hypergeometric distribution.
The hypergeometric distribution is used to calculate a
p-value for this fraction and a 5% FDR is used to correct
for multiple testing. Likewise, a module is considered to
be induced/repressed in a group of samples when a
higher than expected frequency of samples shows induc-
tion/repression of the module. Although the size of the
modules ranged from 1 to 180 genes, the p-value of
altered modules was not related to the number of gene
in each of them (Figure 1).
Quantitative RT-PCR and statistical analysis
Expression of selected genes from altered modules was
analyzed by quantitative reverse transcription-polymer-
ase chain reaction (qRT-PCR) in a ABI Prism
® 7300
Sequence Detection System (Applied Biosystems, Foster
Figure 1 Number of genes represented in each functional
module and p- values for the repressed modules hypothesis.
HNSCC patients were classified according to pathologic lymph node
status (positive or negative) or tumor recurrence (recurrent or non-
recurrent tumor) after treatment (surgery with neck dissection
followed by radiotherapy). Gene expression was assessed by
microarray and functional module analysis was performed.
Functional modules were defined according to the following
databases: Biocarta], GeneDecks, Gene Ontology, and to the Kyoto
Encyclopedia of Genes and Genomes Pathway Database (KEGGPD).
A module is considered to be induced or repressed when it
contains a fraction of induced or repressed genes that is higher
than expected. The p-value of this fraction was calculated using
hypergeometric distribution and a false discovery rate of 5% was
applied to correct multiple testing. A - Negative lymph node (pN0).
B - Non-recurrent tumors. These figures are representative of those
for positive lymph node (pN+) and for recurrent tumors, as well as
for the induced modules hypothesis.
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(Applied Biosystems, Foster City, CA). Three constitu-
tive genes (BCR2, HBMS, and HPRT1) were used to cal-
culate a normalization factor through GeNorm [29].
Primer efficiency was used to calculate the relative
expression to the RNA reference [30]. Median expres-
sion in the analyzed groups was compared using Mann-
Whitney test. Logistic regression model was employed
to identify independent risk factor for lymph node
metastasis (pN+). Kaplan-Meier method was used to
analyze recurrence-free survival and curves were com-
pared with the log-rank test. Cox proportional hazards
model was employed to identify independent risk factors
for recurrence.
Results
Two types of clinical parameters were used to assess the
expression pattern of functional modules associated with
poor prognosis in HNSCC: lymph node metastasis prior
to surgery and recurrence after treatment.
Functional modules related to lymph node metastasis
To analyze the pattern of functional expression asso-
ciated with lymph node metastasis, samples from pri-
mary squamous cell carcinoma of the oral cavity and
oropharynx were collected from previously untreated
patients and classified according pathologic status as
either negative (pN0) or positive (pN+) for lymph node
metastasis.
Functional modules analysis was performed, which
quantify the enrichment of group of genes in samples
profiled by microarray. Specifically, it tests whether the
fraction of over- or under-expressed genes in each sam-
ple is higher than the randomly expected according to
hypergeometric distribution. Next, the analysis assesses
whether particular group of samples (such as pN0 or
pN+) preferentially over- or under-express a certain
module of genes.
Among 334 tested modules, alterations with statistical
significance were found in four modules: Kallikrein
pathway, Protein binding, Regulation of apoptosis, and
Metabolism of xenobiotics by cytochrome P450. As only
as u b s e to fg e n e si nam o d u l em a yc o n t r i b u t et oi t s
expression signature, core results are shown in Table 2
(complete list of altered modules and its genes can be
found in Additional File 2).
The pN+ group showed repression in the Kallikrein
pathway, whereas pN0 tumors showed induction of the
same module. The pN0 group also under-express a
panel of function-restricted gene related to Protein
binding and Regulation of apoptosis (Table 2).
Next, expression of selected genes in altered modules
was analyzed by qRT-PCR. Among the genes that most
contributed to the repression of modules in the pN0
group, CCL20, EGFR, and INHBA were found to be
down-regulated in this group compared to pN+ tumors
(Table 3). Moreover, we fou n dt h a tI N H B Au p - r e g u l a -
tion was associated with lymph node metastasis (N+)
(odds ratio 5.6; 95% confidence interval 1.5 to 21.8; p-
value = 0.012), as well as SERPINA3 down-regulation
(odds ratio 4.0; 95% confidence interval 1.0 to 15.4; p-
value = 0.044) (Table 4).
Functional modules related to locoregional and distant
metastasis
In order to study the expression pattern of functional
modules related to poor prognosis we also checked
medical records for locoregional recurrence and/or dis-
tant metastasis. Follow-up was available for 47 pN+
patients. Twenty of them presented locoregional recur-
rence and/or distant metastases (biopsy proven or by
imaging), and 27 were recurrence/metastasis-free after
treatment.
Functional modules analysis showed alterations in the
Cell-cell signaling and Extracellular region modules
(Table 2, see Additional File 2 for complete list of
altered modules). The cell-cell signaling module was
repressed in non-recurrent tumors and induced in
recurrent tumors. The Extracellular module was also
repressed in non-recurrent tumors. As these two mod-
ule share same genes, there is an overlap between the
genes that most contributed to the repression of both
modules.
Using qRT-PCR, we found that BST-2 was down-
regulated in recurrent tumors (Table 3). Moreover,
BST2 up-regulation was associated with recurrence-free
survival (hazard ratio 8.9; 95% confidence interval 1.2 to
68.7; p-value = 0.035) (Table 4).
Discussion
To understand the complex biology of HNSCC, func-
tional analysis of microarray data was used to identify
groups of genes involved in the development of lymph
node metastasis and recurrence of the disease. We used
the strategy proposed by Segal et al [13] because, unlike
other functional strategies, this analysis is not restricted
to the identification of enriched modules from a list of
differentially expressed genes; the functional modules
analysis is capable of identifying which modules are
induced or and which are repressed in each group of
samples. In addition, our findings show that the use of
existing biological knowledge in the form of module of
genes is valuable tool for understanding tumors with
different prognosis. The functional modules strategy
characterized each condition by a particular combina-
tion of modules, providing important insights into the
gene expression of primary tumors of patients with
lymph node metastasis and recurrent disease. For
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Module Status Gene symbol p-value
Negative lymph node (20 samples)
Protein biding repressed FOSB 4.1E-31
KLK6 5.7E-18
AREG 1.3E-11
CCL20 4.0E-08
IL1B 7.5E-05
MYC 2.0E-04
INHBA 7.0E-03
EGFR 1.4E-02
AKT1 2.1E-02
Regulation of apoptosis repressed SPHK1 9.0E-09
INHBA 9.0E-09
AKT1 9.7E-03
KLK pathway induced KLK13 4.0E-15
KLK7 2.8E-05
KLK6 1.5E-02
SERPINA3 1.7E-02
Positive lymph node (61 samples)
KLK pathway repressed KLK13 4.0E-15
KLK7 2.8E-05
KLK6 1.5E-02
SERPINA3 1.7E-02
Recurrent tumors (20 samples)
Cell-cell signaling induced IL1F9 4.1E-20
AREG 5.5E-15
INHBA 1.5E-12
BST2 7.6E-10
CCL20 2.1E-3
KLK6 8.9E-3
Non-recurrent tumor (27samples)
Cell-cell signaling repressed IL1F9 4.1E-20
AREG 5.5E-15
INHBA 1.5E-12
BST2 7.6E-10
CCL20 2.1E-3
KLK6 8.9E-3
Extracellular region repressed INHBA 6.6E-15
POSTN 3.0E-9
KLK13 1.9E-6
AREG 2.4E-6
MMP13 7.3E-4
KLK6 1.6E-2
HNSCC patients were classified according to pathologic lymph node status (positive or negative) or tumor recurrence (recurrent or non-recurrent tumor) after
treatment (surgery with neck dissection followed by radiotherapy) and samples from primary tumors were collected. Gene expression was assessed by microarray
and functional module analysis was performed. Functional modules were defined according to the following databases: Biocarta], GeneDecks, Gene Ontology,
and to the Kyoto Encyclopedia of Genes and Genomes Pathway Database (KEGGPD).
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quently studied in cancer but also suggest a role for some
genes that have not been previously implicated in HNSCC
or metastasis in general. Based on the literature and on
the pathways presented by KEGGPD, many connections
between these genes could be highlighted (Figure 2).
These connections are summarized below.
Samples from patients with negative lymph node
showed induction of the Kallikrein pathway. SERPINA3
belongs to the Kallikrein pathway, which is induced in
pN0 tumors. SERPINA3 encodes the protease inhibitor
alpha-1-antichymotrypsin, which was previously
reported to inhibit MMP9 activation [31].
The protein binding module is repressed in pN0 tumors
and it is represented by several genes. Inhibin beta A
(INHBA) subunits form a homodimer, activin A, which
stimulates VEGF gene expression in carcinoma cells [32]
and in the v-akt murine thymoma viral oncogene homolog
(AKT) pathway [33]. SPHK1 is a kinase that may promote
growth proliferative advantage and resistance to apoptosis
through activation of the extracellular signal-related
kinases 1/2 (ERK1/2) and phosphatidylinositol 3-kinase
(PI3K)/AKT pathways [34]. SPHK1 can also be activated
by IL-1b [35]. IL1F9 gene is in the same locus as IL1B,
suggesting a common origin [36]. IL1F9 promotes a sig-
naling cascade similar to IL-1, activating NF-B [37]. Cell
survival is also represented here by AKT1,w h i c hp h o s -
phorylates and inactivates the apoptotic machinery (for
review see reference [38]).
Epithelial growth factor receptor (EGFR), which has
shown to be overexpressed in HNSCC in several studies,
plays a critical role in HNSCC growth, invasion, metas-
tasis, and angiogenesis (for review see reference [5]).
Amphiregulin, the protein encoded by AREG, is a ligand
of EGFR. In squamous cell carcinoma cells, amphiregu-
lin is released by MMP cleavage. Moreover, AREG gene
silencing or binding inhibition prevents EGFR phos-
phorylation and downstream events, such as cell prolif-
eration, migration, and activation of the survival
mediator AKT [39]. CCL20, the macrophage inflamma-
tory protein-3a, mediates ERK1/2 activation through a
MMP-dependent release of amphiregulin and transacti-
vation of the EGFR. Again, blockade of amphiregulin
reduced CCL20-mediated cell proliferation [40].
Considering these findings, we suggest that the tumor
biology of pN0 is associated with repression of modules
Table 3 Expression of genes found in altered modules of
head and neck squamous cell carcinoma (HNSCC)
assessed by quantitative reverse transcription-
polymerase chain reaction (qRT-PCR)
Comparison Gene ,p-value, Mann-
Whitney test
Fold
change
Positive lymph node
(61 samples)
CCL20 0.009 3.40
Negative lymph node
(20 samples)
EGFR 0.006 1.70
INHBA 0.014 2.05
IL1B 0.07 1.38
SERPINA3 0.07 -2.43
AKT1 0.13 -
MYC 0.17 -
MCM2 0.22 -
AREG 0.41 -
PCNA 0.43 -
KLK6 0.45 -
FOSB 0.59 -
Recurrent tumors
(20 samples)
BST2 0.014 -1.70
Non-recurrent tumors
(27 samples)
POSTN 0.058 2.47
IL1F9 0.061 1.91
CCL20 0.19 -
INHBA 0.55 -
AREG 0.67 -
KLK6 0.76 -
HNSCC patients were classified according to pathologic lymph node status
(positive or negative) or tumor recurrence (recurrent or non-recurrent tumor)
after treatment (surgery with neck dissection followed by radiotherapy).
Functional module analysis was performed on microarray gene expression
data obtained from primary tumors. Expression of selected genes was
assessed by qRT-PCR.
Table 4 Gene expression associated with lymph node
metastasis and clinical outcome
Logistic regression model
Response variable Gene Odds
ratio
C.I.* 95% p-value
Lymph node
metastasis**
INHBA
(> 4.88)
5.6 1.5-21.8 0.012
SERPINA3
(< 10.74)
4.0 1.0-15.4 0.044
Cox proportional hazards model
Response variable Gene Hazard
ratio
C.I.* 95% p-value
Recurrence-free
survival***
BST2
(< 3.07)
8.9 1.2-68.7 0.035
HNSCC patients were classified according to pathologic lymph node status
(positive or negative) or tumor recurrence (recurrent or non-recurrent tumor)
after treatment (surgery with neck dissection followed by radiotherapy) and
samples from primary tumors were collected. Gene expression was assessed
by quantitative reverse transcription-polymerase chain reaction (qRT-PCR).
Logistic regression model was employed to identify independent risk factor
for lymph node metastasis (pN+). Cox proportional hazards model was
employed to identify independent risk factors for recurrence.
* C.I.: confidence interval.
** Logistic regression model was adjusted by the following variables: CCL20
expression and primary site.
*** Cox proportional hazards model was adjusted by the following variables:
CCL20 expression, primary site, and clinical staging.
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which may be an important factor in lymph node invol-
v e m e n ta sa p o p t o s i si so n eo ft h ep r o c e s s e sr e g u l a t i n g
metastasis (for review see reference [41]).
Gene expression profile of metastatic HNSCC has
been recently described, and the most significantly
altered transcripts in metastatic HNSCC were found to
be associated with adhesion, mobility, and cell survival
[42]. In our study non-recurrent tumors showed signifi-
cantly repressed modules, namely cell-cell signaling and
extracellular region, which contains POSTN. POSTN
encodes periostin, which was implicated in several cellu-
lar functions in cancer. Periostin expression in vitro
leads to EGFR and MMP9 expression [43]. Periostin
may play a role in focal adhesion [44], and promote Akt
activation, leading to tumor and endothelial cell survival
[45]. Periostin may also be important in the epithelial-
mesenchymal transition (EMT). POSTN expression led
to EMT phenotype along with enhanced cell migration,
invasion, and adhesion [43]. In HNSCC cell lines,
periostin promoted distant and lymph node metastases
in a murine model [46]. Periostin is also related to
angiogenesis. In oral SCC, periostin+ samples had
higher blood vessel density and recombinant periostin
enhanced blood vessel formation in vitro [47]. Finally, it
was shown that periostin is expressed by stromal cells
[48] and by fibroblasts in cancer [49]. Therefore, it is
possible that in non-recurrent tumors, in which the
POSTN module is repressed, the stroma has fewer inter-
actions with tumor cells, somehow disabling metastasis
development.
One limitation of this study was that the connections
among genes based on information from the literature
were collected through different types of experiments
done in several forms of cancer. Therefore, we cannot
be sure that these connections really occur in HNSCC.
These findings need to be validated by functional assays
to assess the role they might have in complex and het-
erogeneous cancer cells. Moreover, the modules identi-
fied as induced or repressed were groups of genes that
Figure 2 Literature-based connections among genes in altered modules of head and neck squamous cell carcinoma (HNSCC). HNSCC
patients were classified according to pathologic lymph node status (positive or negative) or tumor recurrence (recurrent or non-recurrent tumor)
after treatment (surgery with neck dissection followed by radiotherapy). Gene expression was assessed by microarray and functional module
analysis was performed. Functional modules were defined according to the following databases: Biocarta], GeneDecks, Gene Ontology, and to
the Kyoto Encyclopedia of Genes and Genomes Pathway Database (KEGGPD). A module is considered to be induced or repressed when it
contains a fraction of induced or repressed genes that is higher than expected. The p-value of this fraction was calculated using hypergeometric
distribution and a false discovery rate of 5% was applied to correct multiple testing. Corrected p-values ranged between 4.1 × 10
-20 and 2.1 ×
10
-2. Filled arrows represent gene connections described in KEGGPD and dotted arrows, connections described elsewhere (see Discussion for
references). Pointed arrows represent activation of gene expression or protein activity, and blunt arrows, inhibition.
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necessarily represent pathways. However, according to
Segal et al [13], many phenomena are sufficiently robust
to be detected using functional modules analysis. So, the
repression of functional categories may suggest that the
main differences between two types of tumors (e. g. N0
and N+) are not in pathways per se, but in cellular func-
tions instead.
In this study, we focused on the biology of the altered
modules in pN0 vs. pN+ and in recurrent vs. non-recur-
rent tumors. The great advantage of the functional mod-
ules strategy is the increased comparability of results
from different microarray studies [50]. Indeed, we iden-
tified altered modules with functions similar to those
described by other authors using different approaches of
functional gene expression in HNSCC. These functions
include cell adhesion, cell death, cell growth and degra-
dation of the extracellular matrix [10]. Up-regulation of
genes that encode for MMP and for proteins related to
inflammatory response was also found [12]. A super-
vised pathway-based analysis was performed in pN0 and
pN+ HNSCC, indicating gene sets involved in extracel-
lular matrix remodeling, hypoxia, and angiogenesis [50].
Three interesting observations can also be extrapo-
lated from our dataset. First, the most frequent altera-
tions found were the repression of modules in pN0 and
in non-recurrent tumors. This also suggests that loss of
various cellular functions may have a negative effect on
the acquisition of the metastatic phenotype. Secondly,
the tumor samples used here are not microdissected, so
the data represent the gene expression of the tumor
together with the stroma. Thus, the genes responsible
for induction/repression of modules may show signaling
between the microenvironment and the tumor cell. The
understanding of how these interactions lead to tumor
progression is critical for improving cancer treatment.
Finally, many of the genes can be implicated in more
than one pathway or more than one characteristic.
Therefore, therapeutic approaches to prevent tumor
progression should target more than one gene or
pathway.
Functional modules analysis also provided interesting
putative biomarkers that have not been previously impli-
cated in HNSCC lymph node metastasis or recurrence.
For instance, BST2 up-regulation was significantly asso-
ciated with disease-free survival. BST2, also known as
bone marrow stromal cell antigen 2, was implicated in
many cellular functions in different cell types, such as
development of B cell precursors [51], actin organization
at the apical membrane of epithelial cells [52], and
tethering HIV virions to cells [53]. Although BST2 func-
tion in HNSCC is unknown, BST2 expression may be
used as prognostic marker to guide treatment. In addi-
tion, we found that INHBA up-regulation and SERPINA3
down-regulation are significantly associated with lymph
node metastasis. This information would be very useful
in routine care of HNSCC because the presence of lymph
node metastasis prior to surgery is not easily determined
by the currently avaible methods.
Conclusions
The alterations identified here offer a comprehensive
initial view of the molecular mechanisms of HNSCC,
suggesting that loss of cell survival and interactions with
the stroma inhibits HNSCC progression. Functional
and/or in vivo studies may determine which genes, path-
ways, and gene set combinations have the greatest
impact on cancer progression, which may contribute for
the improvement of HNSCC treatment.
Additional material
Additional File 1: Genes and modules present in microarray
platform GPL8173. list of all modules represented in the microarray
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